

Evidence dossier - Samantha McLemore - Patient Capital Management

GetCoattail manager profile: <https://getcoattail.com/manager/samantha-mclemore-patient-capital-management> | CIK 0001854794 | Rank #112 of 149 tracked managers by reported 13F value.

Background: Founded: 2020 | HQ: Baltimore, Maryland, U.S. | Style: Long-term intrinsic value, behaviorally focused equity | Key person: Samantha McLemore

Background source: <https://www.patientcm.com/>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-13 Reported total value: \$3.1B Positions: 40 Top-10 concentration: 51.4% of reported value.

Ticker	Company	Weight	Reported value
RPRX	Royalty Pharma Plc	6.61%	\$202M
C	Citigroup Inc	6.44%	\$196M
GOOGL	Alphabet Inc	6.16%	\$188M
UNH	Unitedhealth Group Inc	5.96%	\$182M
AMZN	Amazon Com Inc	5.32%	\$162M
NVDA	Nvidia Corporation	4.65%	\$142M
CVS	Cvs Health Corp	4.19%	\$128M
NCLH	Norwegian Cruise Line Hldgs	4.17%	\$127M
QXO	Qxo Inc	4.04%	\$123M
ET	Energy Transfer L P	3.81%	\$116M

2. Hypothetical 13F-clone results

Window: 2022-02-14 to 2026-10-02 (19 filings). Cumulative: +78.4% CAGR: +13.32% SPY same window: cumulative +86.8%, CAGR +14.45%. Trailing CAGR - 10Y: n/a, 5Y: n/a, 3Y: +26.21%, 1Y: +19.91%. Max drawdown (month-end, approximate): -30.2%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2021Q4	0001085146-22-001017	2022-02-14	38
2022Q1	0001085146-22-002149	2022-05-16	42
2022Q2	0001085146-22-003092	2022-08-15	39
2022Q3	0001085146-22-004043	2022-11-14	41
2022Q4	0001085146-23-001252	2023-02-14	42

2023Q1	0001085146-23-002385	2023-05-15	41
2023Q2	0001085146-23-003400	2023-08-14	44
2023Q3	0001085146-23-004442	2023-11-14	41
2023Q4	0001085146-24-001375	2024-02-14	42
2024Q1	0001085146-24-002548	2024-05-15	42
2024Q2	0001085146-24-003874	2024-08-14	40
2024Q3	0001085146-24-005800	2024-11-14	41
2024Q4	0001085146-25-001553	2025-02-14	43
2025Q1	0001085146-25-003124	2025-05-14	39
2025Q2	0001085146-25-004963	2025-08-13	40
2025Q3	0001854794-25-000004	2025-10-30	41
2025Q4	0001854794-26-000003	2026-02-13	40
2026Q1	0001854794-26-000004	2026-05-14	38
2026Q2	0001854794-26-000005	2026-08-13	39

4. Coverage and adjustments

Price coverage at the latest filing: 87.4% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.